Cell-Free Protein Synthesis Patents: Who Leads, Where the Gaps Are 2026
- Concentrated at the top. The top 5 assignees together account for 55.8% of all 95 records in scope, and the top 10 for 82.1% — a short list controls most of the filed claim space.
- Filing has plateaued, not grown. Annual filings sat flat from 2021 to 2024 (0% change over that span), well below the 2018 peak of 27 records, though 2025-2026 figures are still filling in.
- Almost every record touches microbial and enzymatic synthesis classes. 89.5% of records carry a C12N classification and 85.3% carry C12P, meaning most filings claim the biology itself rather than adjacent measurement or delivery.
Filing growth compares 2021 (1 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 95 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Cell-free protein synthesis systems replace living cells with extracted or reconstituted machinery to manufacture protein directly, and the energy-regeneration subsystem — the enzymes and cofactor cycles that keep ATP available once the cell’s own metabolism is gone — is one of the few components that determines whether a system can run past a few hours. This landscape covers 95 published records filed between 2015 and 2026 that combine cell-free or in-vitro translation claims with energy regeneration or recycling language, filtered to exclude diagnostic and patient-treatment framing so the set stays focused on manufacturing chemistry.
The scope is narrow by design: it is not all of cell-free protein synthesis, only the slice where energy regeneration is claimed explicitly. That narrowness is useful for freedom-to-operate work, but it means broader upstream cell-extract patents sit outside this set even where they touch the same systems.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 95-record set: how filing activity has moved year over year, and which IPC subclasses carry the claims.
A 2018 peak, then a plateau
Filings ran as high as 27 in 2018 and 20 in 2017, then settled into a much lower and flatter pattern — 2021 and 2024 both sit at 1 record, a 0% change over that three-year span. 2025 and 2026 figures will rise as publication catches up with filing, since publication typically lags filing by around 18 months.
Biology-heavy, not tooling-heavy
C12N (microorganisms and genetic engineering) and C12P (fermentation and enzymatic synthesis) cover 89.5% and 85.3% of records respectively, meaning most patents claim the synthesis biology itself. C07K (peptides and proteins) appears in 35.8% of records, while measurement-adjacent classes like C12Q and G01N sit well below 16% — a record can carry multiple classes, so these shares add to more than 100%.
Shares are the percentage of the 95 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell-Free Protein Synthesis — Energy Regeneration Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cell-free protein synthesis — energy regeneration patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe record setting the terms for polyphosphate-based regeneration
US11136586B2 — Cell-free expression system having novel inorganic polyphosphate-based energy regeneration
The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.Filed by Nature's Toolbox, Inc., granted 2021-10-05.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20130316397A1 | Cell-Free Polypeptide Synthesis | 29 |
| 2 | US7235382B2 | Preparation containing cell extracts for cell-free protein synthesis and means for synthesizing protein using… | 25 |
| 3 | US20080138857A1 | Methods of in vitro protein synthesis | 23 |
| 4 | US7176345B2 | Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor | 22 |
| 5 | WO2019033095A1 | Improved in vitro transcription/translation (TXTL) system and use thereof | 21 |
| 6 | EP2610348A1 | Novel artificial translation/synthesis system | 17 |
| 7 | US9701993B2 | Artificial translation/synthesis system | 17 |
| 8 | US20170349928A1 | Methods for activating natural energy metabolism for improving yeast cell-free protein synthesis | 16 |
| 9 | US20130217599A1 | Novel artificial translation/synthesis system | 15 |
| 10 | WO2018165159A1 | Methods and systems for cell-free biodiscovery of natural products | 14 |
Citation counts reward older filings that later art has had time to reference, so treat this as a signal of influence within the corpus rather than of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns worth acting on before drafting claims in this space.
A short list controls most of the claim space
With the top 5 assignees holding 55.8% of all 95 records and the top 10 holding 82.1%, freedom-to-operate work in this niche means checking a small number of portfolios closely rather than scanning a diffuse field.
Flat, not falling
Filing volume has been flat across the last complete comparison window rather than declining — the 2018 peak of 27 records was never repeated, but the lower plateau has held steady rather than eroded further.
Claims sit on the biology, not the periphery
Nearly nine in ten records classify under C12N and over eight in ten under C12P, so most competitive activity is aimed squarely at the synthesis and enzymatic machinery rather than at measurement, delivery or downstream formulation.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell-free protein synthesis — energy regeneration patent landscape, with the prior art for and against each one.
Who is filing, and where the gate sits
The ranked leaders in this set span academic institutes, specialist cell-free biotech firms and a handful of large diversified filers, with a long tail of single-record entrants behind them.
A single filer leads by a wide margin
The top-ranked assignee holds 15 records in this set, well ahead of fifth place at 8 and tenth place at 4 — a gap that suggests a deliberately built portfolio rather than incidental filing.
A cluster of specialist filers
Positions two through five sit closer together, reflecting a set of specialist cell-free biotech firms and research institutes each building a defensible but narrower position rather than one dominant player.
Most filers appear once or twice
The ranking covers 29 companies total, and the drop from tenth place at 4 records down to single-filing entrants shows most organisations in this space have staked one claim rather than built a program.
| Assignee | Recent year | YoY |
|---|---|---|
| Fraunhofer Gesellschaft zur Forderung der angewandten Forschung e.V. | 0 | — |
| SYNVITROBIO INC | 0 | — |
| Nature's Toolbox, Inc. | 0 | — |
| Kangma (Shanghai) Biotech Ltd. | 0 | — |
| NTXBIO LLC | 0 | — |
| Kaneka Corporation | 0 | — |
| Dana-Farber Cancer Institute, Inc. | 0 | — |
| Gene Frontier Corporation | 0 | — |
Where to take this
The dataset points to a few concrete next steps depending on what you're trying to decide.
Map freedom-to-operate against the top 10
With 82.1% of records held by ten assignees, a focused portfolio review of that group covers most of the risk in this niche.
Explore assignee portfolios in EurekaWatch the 2025-2026 publication catch-up
Because publication lags filing by roughly 18 months, the most recent two years in this trend will fill in further — worth rechecking before finalising a filing strategy.
Track filing trends in EurekaProbe the under-claimed branches
Sub-areas like non-E. coli cofactor cycling and thermostable kinase pairings carry far fewer filings than the core C12N/C12P classes.
Search white space in EurekaCommon questions about this landscape
One assignee leads the ranked list with 15 records, noticeably ahead of the rest of the field — fifth place holds 8 and tenth place holds 4. The top 5 assignees combined account for 55.8% of all 95 records in scope, and the top 10 combined account for 82.1%, so the field is concentrated among a small number of specialist and institutional filers rather than spread evenly. A freedom-to-operate check in this space should start with that short list before widening out to the long tail of single-filing entrants.
Filing peaked in 2018 at 27 records, well above the 20 seen in 2017, and has since settled onto a much lower plateau. Comparing the last two complete years available, 2021 and 2024 both sit at 1 record, a 0% change over that span, so the honest reading is flat rather than declining. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by around 18 months, so recent-year counts will rise as more records come through.
The two dominant IPC subclasses are C12N (microorganisms and genetic engineering), covering 89.5% of the 95 records, and C12P (fermentation and enzymatic synthesis), covering 85.3%. C07K (peptides and proteins) appears in 35.8% of records, while measurement- and testing-related classes such as C12Q and G01N appear in well under a fifth of records. Because a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be summed together.
US11136586B2, assigned to Nature's Toolbox, Inc. and granted in 2021, covers a cell-free expression system that regenerates ATP from inorganic polyphosphate using a dual enzyme system, including thermostable adenosyl kinase and polyphosphate kinase enzymes. That places its claim scope specifically around polyphosphate-based ATP regeneration rather than energy regeneration generally, so systems using other cofactor-cycling chemistries — phosphoenolpyruvate or creatine phosphate routes, for example — sit outside its most direct claim language. Anyone designing a polyphosphate-based regeneration system for a commercial cell-free platform should review this patent's claim set closely before finalising an enzyme pairing.
The record set shows heavy concentration in core microbial and enzymatic synthesis classes (C12N, C12P) but much thinner coverage in adjacent areas such as non-E. coli cofactor cycling, thermostable kinase pairings for extended runtime, and coupling of regeneration systems to measurement or QC workflows. These branches appear in the dataset but carry far fewer filings than the core classes, which is where a narrowly drafted claim has more room to stand without colliding with an incumbent's portfolio. Any white-space claim should still be checked against the top 10 assignees, who together hold 82.1% of all 95 records.
Research Cell-Free Protein Synthesis — Energy Regeneration Patent Landscape in depth with Eureka
Go past this page: query the whole cell-free protein synthesis — energy regeneration patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.